Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis

MINGJUN LI¹, WENGANG WANG²*, LI GENG¹, YANRU QIN¹, WENJIE DONG¹, XUDONG ZHANG¹, AN QIN² and MINGZHI ZHANG¹

1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052; 2Department of Orthopedics, Shanghai Key Laboratory of Orthopedic Implant, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China

Received January 18, 2015; Accepted August 13, 2015

DOI: 10.3892/ijmm.2015.2330

Abstract. Astragaloside IV (AS-IV) is a natural plant extract that enhances osteoblast activity, and therefore, has the potential to treat osteoclast-related diseases. Such diseases include osteoporosis, periodontal disease, rheumatoid arthritis and aseptic prosthesis loosening. However, data associating the effects of AS-IV on osteoclasts are limited. The aim of the present study was to assess the effect of AS-IV on osteoclasts in vitro and in vivo. The in vitro studies demonstrated that AS-IV exerts potent inhibitory effects on the ligand of the receptor activator of nuclear factor-κB-induced osteoclastogenesis and revealed the mechanism of action of AS-IV, which inhibited osteoclastogenesis by suppression of the extracellular signal-regulated kinase signaling pathway. The in vivo studies proved that AS-IV attenuated titanium particle-induced osteolysis in a mouse calvarial model. Collectively, the findings of the study suggest that AS-IV is a potential natural agent for the treatment of osteoclast-related diseases.

Introduction

In vivo, the skeleton is constantly being remodeled via a process involving the breakdown (resorption) and build-up (synthesis) of bone, determined by a delicate balance between osteoblast and osteoclast activities (1). As osteoclasts have key roles in the regulation of bone mass and quality, the majority of adult skeletal diseases are due to excess osteoclast activity, resulting in osteopenia (2,3). Such diseases include osteoporosis, periodontal disease, rheumatoid arthritis and aseptic prosthesis loosening (4,5). For individuals with osteoporosis, a condition characterized by low bone mass and skeletal fragility, low trauma bone fractures represent life-threatening events, particularly when they affect the vertebrae, proximal femur (hip), distal forearm or proximal humerus (6).

Osteoclasts are large, multinucleated cells that arise from the hematopoietic stem cell monocyte/macrophage lineage (7). Osteoclast activation was initiated by activation of the receptor activator of the nuclear factor-κB (RANK) and RANK ligand (RANKL) signaling pathways (8,9). RANK and RANKL belong to the tumor necrosis factor (TNF) receptor superfamily (10,11). The binding of RANKL to RANK recruits the adapter protein, TNF receptor-associated factor 6 (TRAF6), to the plasma membrane. RANK, RANKL and TRAF6 are essential for osteoclastogenesis, as mice lacking these molecules show profound bone resorption defects (12). The RANK/TRAF6 complex activates several pathways, including NF-κB signaling and the mitogen-activated protein kinase (MAPK) pathways involving extracellular signal-related kinase (ERK), which induce expression of nuclear factor of activated T cells (NFATc1), considered one of the master transcription factors controlling osteoclastogenesis (13-15). Therefore, ERK and NFATc1, which are closely regulated by MAPK activity, are essential for the differentiation, survival and activation of osteoclasts (16-18).
Astragaloside IV (AS-IV) (Fig. 1) is a saponin purified from Astragalus membranaceus Bge., one of the most widely used Chinese herbs (19). AS-IV has been reported to have a wide range of treatment effects, with no toxicity (20). Pharmacological activities attributed to AS-IV include cardioprotective (21), anti-inflammatory (22), antioxidant (23), anti-asthmatic (24) and anticancer (25) effects. Some of these pharmacological activities resulted from AS-IV-mediated inhibition of ERK (26-28) and NF-κB (26,29-31) signaling pathways. Furthermore, AS-IV has been reported to affect osteogenesis (32), and have anti-arthritis activity (33). All these findings indicated that AS-IV may have a negative effect on osteoclastogenesis and may therefore have a significant potential for the treatment of osteoclast-related diseases, including osteoporosis. However, to the best of our knowledge, there is little published information regarding this issue.

Therefore, the present study aimed to i) investigate the potential therapeutic benefits of AS-IV on osteoclast-related osteolytic bone diseases, ii) understand the underlying mechanisms mediating the effects of AS-IV on osteoclast formation and function, and iii) further elucidate the potential molecular mechanisms of AS-IV in osteoclasts.

Materials and methods

Media, reagents and cells. Fetal bovine serum and α-modification of Eagle’s medium (α-MEM) were obtained from Gibco-BRL (Sydney, Australia). The cell counting kit-8 (CCK-8) was purchased from Dojindo (Kumamoto, Japan). Soluble human recombinant macrophage-colony stimulating factor (M-CSF) and bacteria-derived recombinant mouse RANKL were supplied by R&D Systems (Minneapolis, MN, USA). AS-IV (purity >98%) was purchased from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide prior to dilution to the appropriate concentration in culture medium (34). Western blot-specific antibodies were obtained from Cell Signaling Technology (Cambridge, MA, USA). RAW264.7 cells were purchased from the American Type Culture Collection (Rockville, MD, USA).

Cytotoxicity assay. The cytotoxic effects of AS-IV were determined using a CCK-8 assay. Bone marrow macrophages (BMMs) of C57BL6 mice were seeded in 96-well plates at a density of 8x10³ cells/well, and cultured for 24 h. Cells were subsequently treated with different concentrations of AS-IV for 24, 48, 72 and 96 h. CCK-8 buffer (10 µl) was added to each well, and the cells were incubated with AS-IV (0, 25, 50 or 100 µM) for 2 days until mature osteoclasts had formed. Osteoclasts were identified by positive staining for tartrate-resistant acid phosphatase (TRAP). TRAP-positive cells with >3 nuclei were counted under a microscope.

F-actin ring immunofluorescence. For F-actin ring immunofluorescent staining, osteoclasts were fixed with 4% paraformaldehyde for 15 min at room temperature and permeabilized for 5 min with 0.1% v/v Triton X-100. Cells were incubated with rhodamine-conjugated phalloidin (1:100; Invitrogen, Carlsbad, CA, USA) for 1 h at room temperature. Cells were subsequently incubated with Hoechst 3342 dye (1:5,000) for visualization of the nuclei, washed with phosphate-buffered saline (PBS), and mounted with ProLong Gold anti-fade mounting medium (both from Invitrogen). Fluorescence detection was performed on Nikon A1Si spectral detector confocal system equipped with 20X (dry) lenses (Nikon, Tokyo, Japan). Images were collected using NIS-C elements software and analyzed using ImageJ Software (National Institutes of Health, Bethesda, MD, USA).

Bone resorption pit assay. BMMs were seeded on bone slices in 96-well plates at a density of 8x10³ cells/well and stimulated (in triplicate) with M-CSF (30 ng/ml), RANKL (50 ng/ml) and AS-IV (0, 25, 50 or 100 µM). Bone slices were imaged using field-emission scanning electron microscopy (FESEM, Hitachi S-4800, CamScan; Hitachi, Tokyo, Japan) with a magnification of 10 kV.

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay. RT-qPCR was used to measure specific gene expression. BMMs were plated in 6-well plates at a density of 1x10⁵ cells/well and cultured in complete α-MEM supplemented with 30 ng/ml M-CSF and 50 ng/ml RANKL. For the concentration gradient assay, cells were incubated with AS-IV (0, 25 or 50 µM) for 5-7 days until mature osteoclasts formed. For the time gradient assay, cells were incubated with 50 µM AS-IV for 0, 1, 3 or 5 days. Total RNA was extracted using the Qiagen RNeasy Mini kit (Qiagen, Valencia, CA, USA) and cDNA was synthesized from 1 µg of total RNA using reverse transcriptase (Takara...)
Biotechnology, Otsu, Japan). qPCR was performed using the SYBR Premix Ex Taq kit (Takara Biotechnology) and an ABI 7500 Sequencing Detection system (Applied Biosystems, Foster City, CA, USA) with 40 cycles of denaturation at 95°C for 5 sec and amplification at 60°C for 24 sec. GAPDH was used as the reference gene, and all the reactions were run in triplicate. The mouse primer sequences for cathepsin K (CtsK), TRAP, dendritic cell-specific trans membrane protein (DC-STAMP), V-ATPase d2, c-fos, NFATc1 and GAPDH were as follows: CtsK forward, 5'-CTTCCAATACGTGCA GCAGA-3' and reverse, 5'-TCTTACGGTTCTCTCCTTC-3'; TRAP forward, 5'-CTGGAGTGCAGACGTGAGCAGCA-3' and reverse, 5'-TCCGTGCTCGGGAATTCAAGA-3'; DC-STAMP forward, 5'-AAACCCCTTGGCTTTGTCTTCT-3' and reverse, 5'-GAATCATGGAACACTCTTGG-3'; V-ATPase d2 forward, 5'-AAGCATGGAAGACTGTGGATGG-3' and reverse, 5'-CACATTGGGTCACAGCATCAGC-3'; Western blotting. RAW264.7 cells were seeded in 6-well plates at a density of 1x10⁵ cells/well. The cells were treated 24 h later with different AS-IV concentrations (0, 12.5, 25, 50, 100 or 200 µM) for 1 h, prior to incubation with 50 ng/ml RANKL for a further 8 h. Cells were subsequently lysed and luciferase activity was measured using the Promega Luciferase Assay system (Promega, Madison, WI, USA).

Statistical analysis. The data Are expressed as mean ± standard deviation. The results were analyzed using the analysis of variance and post hoc tests with the SPSS 13.0 software (SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference between groups.

Results

AS-IV cytotoxicity. CCK-8 cell viability assays were performed to examine the potential AS-IV cytotoxicity. The results showed that AS-IV cytotoxicity was concentration- and time-dependent (Fig. 2). These assays indicated that the maximum concentration used in the subsequent studies (200 µM) showed no cytotoxic effects in BMMs, even after 96-h exposure. Based on these data, the AS-IV concentrations used in subsequent experiments were considered non-cytotoxic.

Effect of AS-IV on osteoclastogenesis. As osteoclasts have key roles in osteoclast-related diseases (2), the effect of AS-IV on osteoclastogenesis was investigated. BMMs were exposed to AS-IV (0, 25, 50 and 100 µM) during osteoclast formation. The control group formed numerous TRAP-positive multinucleated osteoclasts (Fig. 3A). Osteoclast formation was inhibited by AS-IV (Fig. 3A-C). Furthermore, comparison of the control and 100 µM AS-IV cells after 3, 5 and 7 days produced similar results (Fig. 3D-F).
et al. ASTRAGALOSIDE IV INHIBITS OSTEOCLASTOGENESIS in vitro AND in vivo

1338

Figure 2. Cytotoxic assays of AS-IV treatment. (A) BMMs were cultured in complete α-modification of Eagle's medium medium containing the indicated concentrations of AS-IV for 24 h. The cell viability, relative to control, was measured by the CCK-8 assay. (B) The inhibition rate of BMMs was calculated using GraphPad Prism software, and the IC_{50} was 1,113 µM. (C) BMM cell viability relative to control was measured by the CCK-8 assay following 48 h incubations with the indicated concentrations of AS-IV. (D) The AS-IV IC_{50} at 48 h was 838.7 µM. (E) The cell viability relative to control was measured by the CCK-8 assay following 72 h incubations with the indicated concentrations of AS-IV. (F) The AS-IV IC_{50} at 72 h was 685.8 µM. (G) The cell viability relative to control was measured by the CCK-8 assay following 96 h incubations with the indicated concentrations of AS-IV. (H) The AS-IV IC_{50} at 96 h was 446.6 µM. *P<0.05 and **P<0.01, compared to 0 µM treatment (control). AS-IV, astragaloside IV; BMMs, bone marrow macrophages; CCK-8, cell counting kit-8; IC_{50}, half-maximal inhibitory concentration.

Figure 3. AS-IV inhibits RANKL-induced osteoclastogenesis. (A) BMMs were treated with different concentrations of AS-IV followed by 30 ng/ml M-CSF and 50 ng/ml RANKL for 5-7 days. Cells were subsequently fixed with 4% paraformaldehyde and stained for TRAP. (B) The number of TRAP-positive cells. (C) The area occupied by TRAP-positive cells. (D) BMMs were treated with or without 100 µM AS-IV, followed by 30 ng/ml M-CSF and 50 ng/ml RANKL. Cells were subsequently fixed and stained for TRAP on days 3, 5 and 7. (E) The number of TRAP-positive cells at the indicated time-points. (F) The area occupied by TRAP-positive cells at the indicated time-points. *P<0.01, compared to 0 µM treatment (control). AS-IV, astragaloside IV; RANKL, receptor activator of the nuclear factor-κB ligand; BMMs, bone marrow macrophages; M-CSF, macrophage colony-stimulating factor; TRAP, tartrate-resistant acid phosphatase.

Osteoclast bone resorption. As the formation of a well-polarized F-actin ring is an essential prerequisite for efficient bone resorption by osteoclasts, we inferred that osteoclast bone resorption would also be inhibited by AS-IV. Numerous bone resorption pits were observed on the surface of control bone slices (Fig. 5). In bone slices exposed to AS-IV, the resorption...
area was decreased. These findings demonstrated that AS-IV impaired osteoclast bone resorption \textit{in vitro}.

**RANKL-induced gene expression.** The expression levels of several specific genes are upregulated during osteoclast differentiation. Thus, RT-qPCR was used to examine and quantify the RANKL-induced mRNA expression of osteoclast-related genes (including NFATc1, TRAP, V-ATPase d2, CtsK, DC-STAMP and c-fos). The results showed that the expression of these genes was inhibited by AS-IV in a dose- and time-dependent manner (Fig. 6).

**RANKL-induced ERK and NFATc1 expression signaling.** RANKL-induced activation of ERK is essential for osteoclast differentiation and function (38,39). The effects of AS-IV on RANKL-induced signaling pathways were therefore investigated. ERK phosphorylation increased within 5-30 min of stimulation with RANKL in the control group. However, ERK phosphorylation was significantly reduced by exposure to AS-IV (Fig. 7A). Quantitative analysis confirmed these results (Fig. 7C). These results suggested that AS-IV inhibited phosphorylation of ERK during osteoclast differentiation.

NFATc1 is an important master regulator of osteoclastogenesis and osteoclast function (40). Therefore, the effects of AS-IV on RANKL-induced NFATc1 expression were investigated. The data presented in Fig. 6A and B indicated that NFATc1 transcriptional activity increased when the cells were stimulated by RANKL. AS-IV inhibited this activity in
Let al: ASTRAGALOSIDE IV INHIBITS OSTEOCLASTOGENESIS in vitro AND in vivo

1340

Figure 6. AS-IV suppresses RANKL-induced expression of osteoclast-specific genes. Bone marrow macrophages were cultured with macrophage colony-stimulating factor (30 ng/ml) and RANKL (50 ng/ml), with or without AS-IV. NFATc1, TRAP, V-ATPase d2, CtsK, DC-STAMP and c-fos expression levels were analyzed by reverse transcription-quantitative polymerase chain reaction and the results were normalized to the expression of glyceraldehyde-3-phosphate dehydrogenase. (A) Levels of the indicated mRNAs following exposure to AS-IV (0, 25 or 50 µM). (B) Levels of the indicated mRNAs following exposure to 50 µM AS-IV for 0, 1, 3 or 5 days. All the experiments were performed at least three times. *P<0.05 and **P<0.01, compared to 0 µM treatment (control). AS-IV, astragaloside IV; RANKL, receptor activator of the nuclear factor-κB ligand; TRAP, tartrate-resistant acid phosphatase; NFATc1, nuclear factor of activated T cells c1.

a dose- and time-dependent manner. To confirm this effect of AS-IV on NFATc1 expression, the NFATc1 protein level was examined using western blot analysis. NFATc1 protein levels increased when cells were exposed to RANKL, and AS-IV attenuated this increase (Fig. 7D and E), suggesting that AS-IV suppressed RANKL-induced NFATc1 expression.

RANKL-induced NF-κB signaling. RANKL-induced NF-κB activation is also a dominant mediator of osteoclast differentiation, resorption function and survival (41-43). Western blot analysis and luciferase assays were used to investigate the NF-κB signaling pathway. Similar levels of IkBα phosphorylation and degradation were observed in control and AS-IV groups (Fig. 7A). This observation was supported by luciferase reporter gene assays (Fig. 7B). These data indicated that AS-IV inhibited osteoclastogenesis without affecting the NF-κB signaling pathway.

Titanium particle-induced osteolysis. To explore the effects of AS-IV on pathological osteolysis, a Ti particle-induced mouse calvarial osteolysis model was used. The degree of particle-induced osteolysis was assessed using high-resolution micro-CT. Compared with the sham group (no Ti particles), the vehicle group (administration of Ti particles in PBS) showed significant calvarial osteolysis. When AS-IV (10 mg/kg, low; 25 mg/kg, high) was administered with the
Ti particles, this osteolytic bone loss reduced (Fig. 8A). Quantitative analysis of bone parameters further demonstrated that the high or low concentrations of AS-IV significantly increased the BV/TV (Fig. 8B), and decreased the number of porosities and the percentage of total porosity in the ROI in the calvaria (Fig. 8C and D).
Discussion

Diseases associated with osteoclasts include osteoporosis, rheumatoid arthritis, multiple myeloma, periprosthetic osteolysis and metastatic cancers (2,44-46). During the last two decades, numerous advances have been made in the treatment of osteoclast-related diseases; however, treatment options are not optimal thus far.

The bisphosphonates were the first drugs approved specifically for the treatment and prevention of osteoclast-related diseases. However, they often cause gastrointestinal toxicity, including dyspepsia, abdominal pain, gastritis and esophagitis. Other serious adverse effects include osteonecrosis of the jaw, femur fractures and atrial fibrillation (47). Estrogens have also been used for the treatment of osteoporosis, but can have serious adverse effects, such as breast cancer, endometrial cancer and thromboembolism (48). The first effective bone anabolic agent teriparatide [parathyroid hormone (PTH) 1-34] has also been used clinically. However, high cost and the requirement for daily subcutaneous injections are major limitations to its use (49). Denosumab is a human monoclonal antibody that inhibits RANKL and, consequently, osteoclastogenesis. However, cellulitis was more frequent in patients taking denosumab compared with the placebo (50) and patients also had a high risk of fractures (51). Strontium ranelate is also used clinically; however, it has the common side effects of nausea, diarrhea, and mild and transient elevation in creatine kinase, and is contraindicated in patients with a high risk of thromboembolic events. In addition, a few cases of hypersensitivity have been reported (52). Due to the limitations of present therapies, attempts to develop improved treatment options are being pursued.

Previous studies indicated that AS-IV had positive effects on osteogenesis (32) and arthritis (33), and to the best of our knowledge, the present study demonstrated for the first time that it significantly inhibited osteoclast differentiation and formation, impaired F-actin ring formation, and significantly decreased the number and area of bone resorption pits in vitro. In the in vivo studies, three-dimensional reconstruction of micro-CT images from mouse calvarias showed that AS-IV treatment markedly suppressed Ti particle-induced osteolysis in a dose-dependent manner.

Activation of RANK by its ligand leads to the expression of osteoclast-specific genes during differentiation, and the activation of resorption by mature osteoclasts (11). RANK signaling is mediated by cytoplasmic factors that activate downstream pathways controlling these various functions. At least five distinct protein kinase-mediated signaling cascades are induced during osteoclastogenesis and activation; inhibitor of NF-kB kinase (IKK), c-Jun N-terminal kinase, p38, ERK and Src pathways (11). ERK is essential for osteoclast differentiation, survival and activation (16,17,53,54). The inhibition of ERK has been proven to possess a therapeutic potential for osteoclast-related diseases (39). Activated ERK stimulates transcription factors, such as NFATc1 (15), which is a master regulator of osteoclast differentiation (40,55,56). Overexpression of NFATc1 accelerates RANKL-induced osteoclast differentiation and can also increase osteoclast formation independently of RANKL. Additionally, NFATc1-deficient embryonic stem cells failed to differentiate into osteoclasts, even in the presence of RANKL (40). Using western blot analysis, AS-IV was revealed to inhibit RANKL-induced ERK signaling. NF-xB was unaffected and this result was confirmed using an NF-xB luciferase reporter assay. AS-IV also inhibited NFATc1 mRNA and protein expression. NFATc1 regulates the expression of a range of genes associated with osteoclast differentiation and function. In the present study, the expression of NFATc1-regulated genes (TRAP, CtsK and V-ATPase d2) was downregulated by AS-IV, suggesting that AS-IV not only affected the expression of NFATc1, but also affected the expression of its downstream genes.

In conclusion, the present study demonstrated that AS-IV had inhibitory effects on osteoclastogenesis and osteoclast function in vitro and in vivo. Additionally, these inhibitory effects appeared to operate via blockade of the ERK and NFATc1 pathways. Taken together, the data strongly suggested that AS-IV may be developed as a potential agent for the treatment of osteoclast-related diseases, including osteoporosis.

Acknowledgements

The present study was supported by the Department of Oncology, The First Affiliated Hospital of Zhengzhou University.

References


